**Supplementary File 2.** Summary of patients who underwent HSCT after SMILE or VIDL chemotherapy.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Characteristics at diagnosis |  | SMILE or VIDL |  | HSCT |  | Post-HSCT | Last follow up status |
| S/A | LDH | B Sx | EBV titer | IPI | Regimen | Number of cycles | Response |  Type  | Conditioning regimen | EBV titer |
| M/16M/28M/36M/56M/34F/61M/49F/55 | NHHHHHHH | +++++++- | -286102641840148133.5257055 | LHIHILIHHILILI |  | SMILESMILEVIDLSMILESMILEVIDLSMILE🡪VIDLSMILE 🡪GDP/L-aspa | 3434431🡪12🡪3 | PRCRCRCRCRCRPD 🡪 PDPD 🡪 PD |  | AutoAlloAlloAlloAlloAlloAlloAllo | Bu-Cy-VP16FluBu4/rATG/TBIFluBu4/rATGFluBu4/rATGFluBu4/rATG/TBIFluBu2/rATGFluBu4/rATGFluBu4/rATG |  | -2---757.280.57- | DiedAliveAliveAliveAliveDiedAliveAlive |

N, normal; H, high; +, presence; -, none; EBV titer: copies/ml; S, sex; A, age; LDH, lactate dehydrogenase; Sx, symptoms; IPI, international prognostic index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; CR, complete response; PR, partial response; Bu-Cy-VP16, busulfan, cyclophosphamide, etoposide; FluBu4/rATG, fludarabine, busulfan, rATG; TBI, total body irradiation